Private Trust Co. NA decreased its position in Sanofi (NASDAQ:SNY – Get Rating) by 13.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,228 shares of the company’s stock after selling 343 shares during the quarter. Private Trust Co. NA’s holdings in Sanofi were worth $108,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in SNY. Price T Rowe Associates Inc. MD grew its stake in shares of Sanofi by 162.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,244,354 shares of the company’s stock valued at $862,735,000 after buying an additional 10,684,509 shares in the last quarter. Boston Partners boosted its position in Sanofi by 48.9% during the third quarter. Boston Partners now owns 17,723,199 shares of the company’s stock worth $677,539,000 after purchasing an additional 5,822,516 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in Sanofi by 276.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after purchasing an additional 2,468,271 shares during the period. Sofinnova Investments Inc. boosted its position in Sanofi by 348.1% during the third quarter. Sofinnova Investments Inc. now owns 1,264,546 shares of the company’s stock worth $48,078,000 after purchasing an additional 982,346 shares during the period. Finally, Kynam Capital Management LP bought a new stake in Sanofi during the third quarter worth approximately $22,812,000. Institutional investors own 10.04% of the company’s stock.
Sanofi Stock Performance
Shares of NASDAQ SNY opened at $54.19 on Wednesday. The business has a fifty day simple moving average of $48.25 and a 200 day simple moving average of $45.53. The company has a current ratio of 1.42, a quick ratio of 1.05 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $136.65 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.62 and a beta of 0.54. Sanofi has a one year low of $36.91 and a one year high of $58.10.
Sanofi Cuts Dividend
The business also recently declared an annual dividend, which will be paid on Friday, June 23rd. Shareholders of record on Wednesday, May 31st will be given a $1.377 dividend. This represents a yield of 2.94%. The ex-dividend date is Tuesday, May 30th. Sanofi’s dividend payout ratio (DPR) is 44.52%.
Analyst Upgrades and Downgrades
SNY has been the subject of a number of recent analyst reports. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, December 2nd. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday. The Goldman Sachs Group initiated coverage on Sanofi in a research report on Friday, December 16th. They set a “buy” rating for the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Sanofi in a research report on Tuesday, December 13th. Finally, Barclays upgraded Sanofi from an “equal weight” rating to an “overweight” rating in a report on Monday. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $98.11.
About Sanofi
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.
Further Reading
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Get Rating).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
